miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.

导出原文传递

翻译打印收藏纠错

第一作者： Konstantina,Panoutsopoulou

第一单位： Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.

作者： Konstantina,Panoutsopoulou ^[1] ; Margaritis,Avgeris ^[1] ; Paraskevi,Magkou ^[1] ; Konstantinos,Mavridis ^[1] ; Tobias,Dreyer ^[2] ; Julia,Dorn ^[2] ; Eva,Obermayr ^[3] ; Alexander,Reinthaller ^[3] ; Kleita,Michaelidou ^[1] ; Sven,Mahner ^[4] ; Ignace,Vergote ^[5] ; Liselore,Loverix ^[5] ; Ioana,Braicu ^[6] ; Jalid,Sehouli ^[6] ; Robert,Zeillinger ^[3] ; Viktor,Magdolen ^[2] ; Andreas,Scorilas ^[1]

作者单位： Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. ^[1] Clinical Research Unit, Department of Obstetrics and Gynecology, School of Medicine, Technical University of Munich, Munich, Germany. ^[2] Molecular Oncology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center-Gynecologic Cancer Unit, Medical University of Vienna, Vienna, Austria. ^[3] Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany. ^[4] Department of Gynecologic Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven, Leuven, Belgium. ^[5] Department of Gynecology, Charité University Medicine, Campus Virchow, Berlin, Germany. ^[6]

关键词 epithelial ovarian cancer microRNA-181a molecular diagnostics noncoding RNA ovarian tumors